You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Insulin Articles
Popular Insulin Articles
Highly Recommended Insulin Articles
Send a link to this page to your friends and colleagues.
Insulin aspart, Novo Nordisk's rapid-acting insulin, has been cleared for sale in Europe under the brand name Novo Rapid. Its arrival on the United States market still depends on the outcome of court battles between Novo Nordisk and its insulin-manufacturing competitor, Eli Lilly.
Like Lilly's Humalog, insulin aspart is designed for injection just before a meal. Lilly is claiming that insulin aspart is so much like Humalog that Novo Nordisk is infringing on its patent. Lilly filed a patent infringement suit in the United Kingdom claiming that Novo Nordisk threatens insulin aspart's future in the United States.
To counter Lilly's attack, Novo Nordisk asked a U.S. court to invalidate Lilly's patent or rule that insulin aspart does not infringe on the Humalog patent. No court date has been set to decide on this legislation.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.